Skip to content

Wirksamkeit und Verträglichkeit von Kneipp Arnika Salbe S bei stumpfen Sportverletzungen im Vergleich zu Ibutop Creme (Efficacy and Safety of Kneipp Arnika Salbe S for blunt impact sport injuries compared to Ibutop Creme) - Arnika Salbe S bei Sportverletzungen

Wirksamkeit und Verträglichkeit von Kneipp Arnika Salbe S bei stumpfen Sportverletzungen im Vergleich zu Ibutop Creme (Efficacy and Safety of Kneipp Arnika Salbe S for blunt impact sport injuries compared to Ibutop Creme) - Arnika Salbe S bei Sportverletzungen

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-002168-84-DE
Enrollment
Unknown
Registered
2007-08-10
Start date
2008-01-07
Completion date
Unknown
Last updated
2012-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with blunt impact injuries (traumatic injuries) MedDRA version: 9.1 Level: LLT Classification code 10044528 Term: Traumatic injury

Interventions

Trade Name: Kneipp Arnika Salbe S Pharmaceutical Form: Ointment Other descriptive name: ARNICA FLOWER Concentration type: range Concentration number: 1:3,5-1:4,5 Trade Name: Ibutop Creme Pharmaceutic

Sponsors

Kneipp-Werke
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: blunt impact injury (not older than 1 hour), Age > 18 years, Force-induced pain reaction (meassured in N) on injured side must be above 150% of pain reaction on contralateral uninjured site, Informed consent acc. to § 40 AMG (German Drug Law) Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Severe injury with e.g. massive swelling, rupture of ligament or fracture of the bone, Open wound; Any local or systemic drug treatment of the acute injury prior to enrolement, Systemic treatment with NSAIDs, anagesics or steroids 2 days prior to enrolement and during the study, Allergy or Hypersensitivity to any compenents of IMPs Pregnancy and/or Nursing Concurrent participation in another clinical trial Drug or alcohol abuse

Design outcomes

Primary

MeasureTime frame
Main Objective: Influence of Arnika Salbe S compared to Ibutop Creme on induced pain reaction (Area under the curve of 6 hours treatment);Secondary Objective: Influence of Arnika Salbe S compared to Ibutop Creme on induced pain reaction (Area under the curve of 24 hours treatment) Influence of Arnika Salbe S compared to Ibutop Creme on passive movement pain Proportion of patients being symptom free at the end of treatment Time period to start sport activities again after start of treatment Global judgement of efficacy and safety by patient ;Primary end point(s): Area under the curve over 6 hours for quotient of force-induced pain reaction (pain reaction injured side / pain reaction contralateral unijured side)

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026